Trump MFN drug pricing policy seen reshaping pharma investment flows
President Donald Trump’s “most-favoured nation” drug pricing policy may boost affordability, with the biggest impact potentially shifting global pharma investment flows.
President Donald Trump's "most-favoured nation" (MFN) drug pricing policy may be getting the most attention for its promise to make healthcare more affordable for Americans, but its biggest impact could be on global pharma investment flows. The White House has suggested the policy could redirect investment and reshape where drugmakers choose to allocate capital, with implications for winners and losers across the pharmaceutical sector.